The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
PHASE4CompletedINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
September 1, 2020
Primary Completion Date
November 18, 2022
Study Completion Date
November 18, 2022
Conditions
Atopic DermatitisEczema
Interventions
BIOLOGICAL
Dupilumab Prefilled Syringe
open-label
Trial Locations (1)
45231
Bernstein Clinical Research Center, Cincinnati
All Listed Sponsors
lead
Jonathan A. Bernstein, MD
OTHER
NCT04358224 - The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment | Biotech Hunter | Biotech Hunter